All In MedTech

FDA Clearance Tracker · P160048-S007

Eversense Continuous Glucose Monitoring System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 15, 2019 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jan 15, 2019

Approved

Time to decision

48 days

Received Nov 28, 2018. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P160048-S007
Device name
Eversense Continuous Glucose Monitoring System
Applicant location
Germantown, MD
Received
Nov 28, 2018
Decided
Jan 15, 2019
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160048

Device type

Device class
Class III

Every decision under product code QCD

FDA's approval statement

As written in FDA's record.

Approval for modification to the approved post-approval study protocol to include nurse practitioners and physicians assistants, in addition to physicians, as practitioners who will perform sensor insertions and removals.

Source documents

Other decisions for Senseonics, Incorporated

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.